Related Experiment Videos
Pattern of drug usage in bronchiolitis
1Colleges of Pharmacy and Medicine, Ohio State University, Columbus 43210.
Insights
This study examined drug use in infants and young children with bronchiolitis, finding significant variation in medication dosages and treatment durations. Further research is needed to establish optimal treatment protocols for this common pediatric respiratory illness.
Area of Science:
- Pediatric Respiratory Medicine
- Clinical Pharmacology
- Infectious Diseases
Background:
- Bronchiolitis is a frequent viral respiratory infection affecting infants and young children.
- Respiratory Syncytial Virus (RSV) is a primary causative agent in pediatric bronchiolitis cases.
Purpose of the Study:
- To evaluate the current patterns of drug utilization in pediatric patients diagnosed with bronchiolitis.
- To identify common therapeutic agents and their application in managing bronchiolitis.
Main Methods:
- A cohort of 100 pediatric patients (2 weeks to 22 months) with bronchiolitis was analyzed.
- Data on administered medications, including albuterol, corticosteroids, aminophylline, and ribavirin, were collected and reviewed.
Main Results:
- Respiratory Syncytial Virus (RSV) infection was confirmed in 64% of the evaluated patients.
- Albuterol was used in 99% of cases, corticosteroids in 36%, aminophylline in 12%, and ribavirin in 2%.
- Significant variability was observed in drug dosing, frequency, and treatment duration across patients.
Conclusions:
- Current drug therapy for pediatric bronchiolitis exhibits considerable heterogeneity.
- There is a critical need for robust clinical research to define evidence-based, optimal dosage regimens and treatment guidelines.
Abstract:
Bronchiolitis is a common viral respiratory infection in infants and young children. The objective of this study was to assess the pattern of drug usage in paediatric patients with bronchiolitis. One hundred patients (aged 2 weeks to 22 months) were evaluated. Of these, 64% had a respiratory syncytial virus infection. The drug therapy included albuterol in 99%, corticosteroids in 36%, aminophylline in 12% and ribavirin in 2% of the patients. The drug doses and frequencies, and durations of therapy varied substantially among patients. This emphasizes the need for well-designed research to develop optimal dosage regimens in paediatric patients with bronchiolitis.